BR112016001106A2 - - Google Patents
Info
- Publication number
- BR112016001106A2 BR112016001106A2 BR112016001106A BR112016001106A BR112016001106A2 BR 112016001106 A2 BR112016001106 A2 BR 112016001106A2 BR 112016001106 A BR112016001106 A BR 112016001106A BR 112016001106 A BR112016001106 A BR 112016001106A BR 112016001106 A2 BR112016001106 A2 BR 112016001106A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2013055906 | 2013-07-18 | ||
| PCT/EP2014/065351 WO2015007830A1 (en) | 2013-07-18 | 2014-07-17 | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016001106A2 true BR112016001106A2 (enExample) | 2017-07-25 |
| BR112016001106A8 BR112016001106A8 (pt) | 2017-12-26 |
Family
ID=51205401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016001106A BR112016001106A8 (pt) | 2013-07-18 | 2014-07-17 | Derivados de espiro [2,4] heptano interligados piperazina substituídos como agonistas do receptor de alx |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9533964B2 (enExample) |
| EP (1) | EP3022188B1 (enExample) |
| JP (1) | JP6330038B2 (enExample) |
| KR (1) | KR20160033747A (enExample) |
| CN (1) | CN105377824B (enExample) |
| AU (1) | AU2014292064B2 (enExample) |
| BR (1) | BR112016001106A8 (enExample) |
| CA (1) | CA2915757A1 (enExample) |
| ES (1) | ES2639798T3 (enExample) |
| MX (1) | MX360699B (enExample) |
| RU (1) | RU2016105310A (enExample) |
| TW (1) | TW201536289A (enExample) |
| WO (1) | WO2015007830A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016105310A (ru) | 2013-07-18 | 2017-08-23 | Актелион Фармасьютиклз Лтд | Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| MX377796B (es) | 2014-05-13 | 2025-03-11 | Novartis Ag | Compuestos y composiciones para inducir condrogenesis. |
| EP3303284B1 (en) | 2015-05-27 | 2020-04-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| AR104751A1 (es) | 2015-05-27 | 2017-08-09 | Kyorin Seiyaku Kk | Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995002587A1 (en) | 1993-07-16 | 1995-01-26 | Merck & Co., Inc. | Substituted piperazinylcamphor derivatives as oxytocin antagonists |
| AU2000227546B2 (en) | 2000-02-04 | 2007-08-30 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infection |
| US20050164305A1 (en) | 2002-04-03 | 2005-07-28 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1) |
| WO2005047899A2 (en) | 2003-11-07 | 2005-05-26 | Acadia Pharmaceuticals Inc. | Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation |
| AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
| TWI434685B (zh) | 2007-12-18 | 2014-04-21 | Actelion Pharmaceuticals Ltd | 胺基三唑衍生物 |
| ES2431298T3 (es) * | 2009-05-18 | 2013-11-25 | Actelion Pharmaceuticals Ltd. | Derivados de espiro[2.4]heptano puenteados como agonistas del receptor de ALX y/o FPRL2 |
| MY161243A (en) | 2009-06-09 | 2017-04-14 | Actelion Pharmaceuticals Ltd | Fluorinated aminotriazole derivatives |
| CN102803237B (zh) | 2009-06-12 | 2014-09-24 | 埃科特莱茵药品有限公司 | 作为alx受体激动剂的噁唑和噻唑衍生物 |
| EP2585054A1 (en) | 2010-06-24 | 2013-05-01 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| CA2814826C (en) * | 2010-11-17 | 2019-02-12 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
| PT2649068E (pt) | 2010-12-07 | 2014-12-23 | Actelion Pharmaceuticals Ltd | Derivados de éter oxazolil-metílico como agonistas do receptor de alx |
| JP5923108B2 (ja) | 2010-12-07 | 2016-05-24 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ａｌｘ受容体アゴニストとしてのヒドロキシル化アミノトリアゾール誘導体 |
| EP2731931A1 (en) | 2011-07-11 | 2014-05-21 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| ES2596521T3 (es) * | 2012-05-16 | 2017-01-10 | Actelion Pharmaceuticals Ltd. | Derivados de espiro[2.4]heptano sustituidos con puente 1-(p-tolil)ciclopropilo como agonistas de receptor de ALX |
| MA37618B1 (fr) * | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| BR122017004254B1 (pt) | 2013-03-06 | 2021-04-13 | Allergan, Inc. | Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares |
| BR112015021392B1 (pt) | 2013-03-06 | 2021-11-16 | Allergan, Inc | Uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas |
| RU2016105310A (ru) | 2013-07-18 | 2017-08-23 | Актелион Фармасьютиклз Лтд | Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
-
2014
- 2014-07-17 RU RU2016105310A patent/RU2016105310A/ru unknown
- 2014-07-17 BR BR112016001106A patent/BR112016001106A8/pt not_active IP Right Cessation
- 2014-07-17 MX MX2016000731A patent/MX360699B/es active IP Right Grant
- 2014-07-17 EP EP14739472.0A patent/EP3022188B1/en not_active Not-in-force
- 2014-07-17 AU AU2014292064A patent/AU2014292064B2/en not_active Ceased
- 2014-07-17 WO PCT/EP2014/065351 patent/WO2015007830A1/en not_active Ceased
- 2014-07-17 CA CA2915757A patent/CA2915757A1/en not_active Abandoned
- 2014-07-17 CN CN201480039969.8A patent/CN105377824B/zh not_active Expired - Fee Related
- 2014-07-17 ES ES14739472.0T patent/ES2639798T3/es active Active
- 2014-07-17 US US14/905,768 patent/US9533964B2/en not_active Expired - Fee Related
- 2014-07-17 KR KR1020167004127A patent/KR20160033747A/ko not_active Withdrawn
- 2014-07-17 JP JP2016526635A patent/JP6330038B2/ja not_active Expired - Fee Related
- 2014-07-17 TW TW103124607A patent/TW201536289A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016001106A8 (pt) | 2017-12-26 |
| TW201536289A (zh) | 2015-10-01 |
| AU2014292064A1 (en) | 2016-03-03 |
| MX2016000731A (es) | 2016-04-13 |
| JP6330038B2 (ja) | 2018-05-23 |
| KR20160033747A (ko) | 2016-03-28 |
| AU2014292064B2 (en) | 2018-07-05 |
| US9533964B2 (en) | 2017-01-03 |
| MX360699B (es) | 2018-11-14 |
| US20160152584A1 (en) | 2016-06-02 |
| EP3022188A1 (en) | 2016-05-25 |
| ES2639798T3 (es) | 2017-10-30 |
| CN105377824A (zh) | 2016-03-02 |
| WO2015007830A1 (en) | 2015-01-22 |
| CA2915757A1 (en) | 2015-01-22 |
| RU2016105310A (ru) | 2017-08-23 |
| EP3022188B1 (en) | 2017-06-07 |
| JP2016525107A (ja) | 2016-08-22 |
| CN105377824B (zh) | 2017-08-04 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
| B25C | Requirement related to requested transfer of rights |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
| B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2471 DE 15-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |